Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2015-10-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate how effective and how safe the combination of
radiation therapy and an investigational medication targeting the immune system known as
Ipilimumab in the treatment of metastatic non-small cell lung cancer (NSCLC).
The investigators would like to see if this combination of radiation and Ipilimumab can
stimulate the body's immune system to stop the growth of tumors that are outside the field of
radiation. The investigators would like see if using this combination of radiation therapy
with Ipilimumab could help the body reject the patient's own tumor or at least help their
immune system to maintain the disease stable and/or slow its growth.
Radiation therapy (RT) is currently a standard procedure for treatment of NSCLC. Ipilimumab
is considered an investigational medication because it is not approved by the Food and Drug
Administration (FDA) for the treatment of NSCLC. Ipilimumab has been approved by the FDA for
the treatment of metastatic melanoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health